Although previous studies showed higher CSF orexin-A concentrations in patients with neurocognitive disorders, most of them included only patients with AD compared to controls; therefore, a general agreement has not been yet achieved [9–18, 28–33]. Here, HCRT is linked to Alzheimer disease.